| Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
| Q37160391 | A systematic review of infliximab in the treatment of early rheumatoid arthritis |
| Q36055449 | An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists |
| Q40138981 | Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study |
| Q51255641 | Contribution of ethnic group and socioeconomic status to degree of disability in rheumatoid arthritis in Chilean patients. |
| Q34550160 | Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide |
| Q41963113 | Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q36100671 | International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review |
| Q33826225 | Leflunomide: a review of its use in active rheumatoid arthritis |
| Q33871797 | Patterns of psychosocial risk and long-term outcomes in rheumatoid arthritis |
| Q34471991 | Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis |
| Q37101353 | The effect of the microscopic and nanoscale structure on bone fragility |